Curtis Oltmans has been appointed General Counsel, Array BioPharma. Mr. Oltmans brings 25 years of experience in the biopharmaceutical industry working on legal matters related to commercialization, litigation, medical, regulatory affairs, intellectual property, corporate governance, mergers and acquisitions, strategic alliances and financial transactions. His appointment will support Array’s efforts as it moves towards potential commercialization. 

Mr. Oltmans most recently served as corporate vice president and general counsel, North America, at Novo Nordisk, where he was responsible for strategy and initiatives in the areas of law, including litigation and intellectual property, and public affairs for the company’s substantial business in North America. Prior to Novo Nordisk, he spent 13 years at Eli Lilly and Company in a variety of legal roles, including litigation, FDA regulatory and international law.

“Curt brings to Array extensive legal and pharmaceutical experience with a record of achievement in developing and leading legal and business initiatives for pharmaceutical companies,” said Ron Squarer, chief executive officer. “As our general counsel, Curt will be responsible for developing and managing our company’s legal and compliance strategies and related functional areas.  He will also fill an important role as a key member of Array’s Executive Committee. We are delighted to welcome Curt to our company.”

Mr. Oltmans succeeds John R. Moore, who has announced his retirement as vice president and general counsel. Mr. Moore will remain with Array through September 8, 2017.